カテゴリ： Transparency Market Research, 世界, 医療/バイオ

強心薬の世界市場2023～2031：薬剤別

■ 英語タイトル：Cardiotonic Agents Market (Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23MA091）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23MA091
■ 発行日：2023年3月29日
■ 調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
■ 産業分野：医薬品
■ ページ数：235
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥869,250見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,319,250見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,769,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[強心薬の世界市場2023～2031：薬剤別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の当調査レポートでは、世界の強心薬市場規模が、2023年の732百万ドルから2031年に45億ドルとなり、予測期間中に年平均成長率21.3%で拡大すると展望しています。本書は、強心薬の世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（ジギタリス配糖体、ホスホジエステラーゼ阻害剤、心保護薬、交感神経刺激薬、その他）分析、用途別（心臓外科手術、心房細動、心不全、肺高血圧症、その他）分析、投与経路別（経口、非経口）分析、剤形別（錠剤、液体、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Amneal Pharmaceuticals LLC、Pfizer Inc.、Hikma Pharmaceuticals PLC、Fresenius Kabi、Midas Pharma GmbH、Sanofi、Aurobindo Pharma Limited、SimSon Pharma Limited、Other Playersなどの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の強心薬市場規模：薬剤別
- ジギタリス配糖体の市場規模
- ホスホジエステラーゼ阻害剤の市場規模
- 心保護薬の市場規模
- 交感神経刺激薬の市場規模
- その他薬剤の市場規模
・世界の強心薬市場規模：用途別
- 心臓外科手術における市場規模
- 心房細動における市場規模
- 心不全における市場規模
- 肺高血圧症における市場規模
- その他用途における市場規模
・世界の強心薬市場規模：投与経路別
- 経口における市場規模
- 非経口投与における市場規模
・世界の強心薬市場規模：剤形別
- 錠剤における市場規模
- 液体における市場規模
- その他剤型における市場規模
・世界の強心薬市場規模：地域別
- 北米の強心薬市場規模
- ヨーロッパの強心薬市場規模
- アジア太平洋の強心薬市場規模
- 中南米の強心薬市場規模
- 中東・アフリカの強心薬市場規模
・競争状況

Cardiotonic Agents Market – Scope of Report
TMR’s report on the global cardiotonic agents market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiotonic agents market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiotonic agents market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiotonic agents market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiotonic agents market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiotonic agents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiotonic agents market.

The report delves into the competitive landscape of the global cardiotonic agents market. Key players operating in the global cardiotonic agents market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiotonic agents market profiled in this report.

Key Questions Answered in Global Cardiotonic Agents Market Report
• What is the sales/revenue generated by cardiotonic agents across all regions during the forecast period?
• What are the opportunities in the global cardiotonic agents market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiotonic Agents Market – Research Objectives and Research Approach
The comprehensive report on the global cardiotonic agents market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiotonic agents market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiotonic agents market.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiotonic Agents Market
4. Market Overview
    4.1. Introduction
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cardiotonic Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Key Industry Events
    5.2. Technological Advancements
    5.3. Value Chain Analysis
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Cardiotonic Agents Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Digitalis Glycosides
        6.3.2. Phosphodiesterase Inhibitors
        6.3.3. Cardioprotectants
        6.3.4. Sympathomimetic Agents
        6.3.5. Others
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Cardiotonic Agents Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Cardiac Surgical Procedures
        7.3.2. Atrial Fibrillation
        7.3.3. Heart Failure
        7.3.4. Pulmonary Hypertension
        7.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    7.4. Market Attractiveness Analysis, by Application
8. Global Cardiotonic Agents Market Analysis and Forecast, by Route of Administration
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Route of Administration, 2017–2031
        8.3.1. Oral
        8.3.2. Parenteral
    8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Cardiotonic Agents Market Analysis and Forecast, by Dosage Form
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Dosage Form, 2017–2031
        9.3.1. Tablet
        9.3.2. Solution
        9.3.3. Others
    9.4. Market Attractiveness Analysis, by Dosage Form
10. Global Cardiotonic Agents Market Analysis and Forecast, by Distribution Channel
    10.1. Introduction & Definition
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by Distribution Channel, 2017–2031
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Online Pharmacies
    10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Cardiotonic Agents Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region, 2017–2031
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness Analysis, by Region
12. North America Cardiotonic Agents Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017–2031
        12.2.1. Digitalis Glycosides
        12.2.2. Phosphodiesterase Inhibitors
        12.2.3. Cardioprotectants
        12.2.4. Sympathomimetic Agents
        12.2.5. Others
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Cardiac Surgical Procedures
        12.3.2. Atrial Fibrillation
        12.3.3. Heart Failure
        12.3.4. Pulmonary Hypertension
        12.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    12.4. Market Value Forecast, by Route of Administration, 2017–2031
        12.4.1. Oral
        12.4.2. Parenteral
    12.5. Market Value Forecast, by Dosage Form, 2017–2031
        12.5.1. Tablet
        12.5.2. Solution
        12.5.3. Others
    12.6. Market Value Forecast, by Distribution Channel, 2017–2031
        12.6.1. Hospital Pharmacies
        12.6.2. Retail Pharmacies
        12.6.3. Online Pharmacies
    12.7. Market Value Forecast, by Country, 2017–2031
        12.7.1. U.S.
        12.7.2. Canada
    12.8. Market Attractiveness Analysis
        12.8.1. By Drug Type
        12.8.2. By Application
        12.8.3. By Route of Administration
        12.8.4. By Dosage Form
        12.8.5. By Distribution Channel
        12.8.6. By Country
13. Europe Cardiotonic Agents Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017–2031
        13.2.1. Digitalis Glycosides
        13.2.2. Phosphodiesterase Inhibitors
        13.2.3. Cardioprotectants
        13.2.4. Sympathomimetic Agents
        13.2.5. Others
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Cardiac Surgical Procedures
        13.3.2. Atrial Fibrillation
        13.3.3. Heart Failure
        13.3.4. Pulmonary Hypertension
        13.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    13.4. Market Value Forecast, by Route of Administration, 2017–2031
        13.4.1. Oral
        13.4.2. Parenteral
    13.5. Market Value Forecast, by Dosage Form, 2017–2031
        13.5.1. Tablet
        13.5.2. Solution
        13.5.3. Others
    13.6. Market Value Forecast, by Distribution Channel, 2017–2031
        13.6.1. Hospital Pharmacies
        13.6.2. Retail Pharmacies
        13.6.3. Online Pharmacies
    13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.7.1. Germany
        13.7.2. U.K.
        13.7.3. France
        13.7.4. Italy
        13.7.5. Spain
        13.7.6. Rest of Europe
    13.8. Market Attractiveness Analysis
        13.8.1. By Drug Type
        13.8.2. By Application
        13.8.3. By Route of Administration
        13.8.4. By Dosage Form
        13.8.5. By Distribution Channel
        13.8.6. By Country/Sub-region
14. Asia Pacific Cardiotonic Agents Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017–2031
        14.2.1. Digitalis Glycosides
        14.2.2. Phosphodiesterase Inhibitors
        14.2.3. Cardioprotectants
        14.2.4. Sympathomimetic Agents
        14.2.5. Others
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Cardiac Surgical Procedures
        14.3.2. Atrial Fibrillation
        14.3.3. Heart Failure
        14.3.4. Pulmonary Hypertension
        14.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    14.4. Market Value Forecast, by Route of Administration, 2017–2031
        14.4.1. Oral
        14.4.2. Parenteral
    14.5. Market Value Forecast, by Dosage Form, 2017–2031
        14.5.1. Tablet
        14.5.2. Solution
        14.5.3. Others
    14.6. Market Value Forecast, by Distribution Channel, 2017–2031
        14.6.1. Hospital Pharmacies
        14.6.2. Retail Pharmacies
        14.6.3. Online Pharmacies
    14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.7.1. China
        14.7.2. Japan
        14.7.3. India
        14.7.4. Australia & New Zealand
        14.7.5. Rest of Asia Pacific
    14.8. Market Attractiveness Analysis
        14.8.1. By Drug Type
        14.8.2. By Application
        14.8.3. By Route of Administration
        14.8.4. By Dosage Form
        14.8.5. By Distribution Channel
        14.8.6. By Country/Sub-region
15. Latin America Cardiotonic Agents Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Type, 2017–2031
        15.2.1. Digitalis Glycosides
        15.2.2. Phosphodiesterase Inhibitors
        15.2.3. Cardioprotectants
        15.2.4. Sympathomimetic Agents
        15.2.5. Others
    15.3. Market Value Forecast, by Application, 2017–2031
        15.3.1. Cardiac Surgical Procedures
        15.3.2. Atrial Fibrillation
        15.3.3. Heart Failure
        15.3.4. Pulmonary Hypertension
        15.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    15.4. Market Value Forecast, by Route of Administration, 2017–2031
        15.4.1. Oral
        15.4.2. Parenteral
    15.5. Market Value Forecast, by Dosage Form, 2017–2031
        15.5.1. Tablet
        15.5.2. Solution
        15.5.3. Others
    15.6. Market Value Forecast, by Distribution Channel, 2017–2031
        15.6.1. Hospital Pharmacies
        15.6.2. Retail Pharmacies
        15.6.3. Online Pharmacies
    15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.7.1. Brazil
        15.7.2. Mexico
        15.7.3. Rest of Latin America
    15.8. Market Attractiveness Analysis
        15.8.1. By Drug Type
        15.8.2. By Application
        15.8.3. By Route of Administration
        15.8.4. By Dosage Form
        15.8.5. By Distribution Channel
        15.8.6. By Country/Sub-region
16. Middle East & Africa Cardiotonic Agents Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Drug Type, 2017–2031
        16.2.1. Digitalis Glycosides
        16.2.2. Phosphodiesterase Inhibitors
        16.2.3. Cardioprotectants
        16.2.4. Sympathomimetic Agents
        16.2.5. Others
    16.3. Market Value Forecast, by Application, 2017–2031
        16.3.1. Cardiac Surgical Procedures
        16.3.2. Atrial Fibrillation
        16.3.3. Heart Failure
        16.3.4. Pulmonary Hypertension
        16.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
    16.4. Market Value Forecast, by Route of Administration, 2017–2031
        16.4.1. Oral
        16.4.2. Parenteral
    16.5. Market Value Forecast, by Dosage Form, 2017–2031
        16.5.1. Tablet
        16.5.2. Solution
        16.5.3. Others
    16.6. Market Value Forecast, by Distribution Channel, 2017–2031
        16.6.1. Hospital Pharmacies
        16.6.2. Retail Pharmacies
        16.6.3. Online Pharmacies
    16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
        16.7.1. GCC Countries
        16.7.2. South Africa
        16.7.3. Rest of Middle East & Africa
    16.8. Market Attractiveness Analysis
        16.8.1. By Drug Type
        16.8.2. By Application
        16.8.3. By Route of Administration
        16.8.4. By Dosage Form
        16.8.5. By Distribution Channel
        16.8.6. By Country/Sub-region
17. Competition Landscape
    17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    17.2. Market Share Analysis, by Company (2022)
    17.3. Company Profiles
        17.3.1. Amneal Pharmaceuticals LLC
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Product Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. Pfizer Inc.
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Product Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. Hikma Pharmaceuticals PLC
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Product Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. Fresenius Kabi
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Product Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. Midas Pharma GmbH
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Product Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. Sanofi
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Product Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. Aurobindo Pharma Limited
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Product Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. SimSon Pharma Limited
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Product Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Other Players
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Product Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview

List of Tables

Table 01: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 05: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 07: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 08: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 11: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 13: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 14: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 16: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 18: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 20: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 26: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 28: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 29: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 31: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 33: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 34: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 35: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 増殖糖尿病網膜症の世界市場2023～2031：薬剤クラス別、投与形態別
  • RAS作用薬の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • バソプレシン拮抗薬の世界市場2023～2031：用途別
  • DNA修復薬の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23MA091 )"強心薬の世界市場2023～2031：薬剤別" (英文：Cardiotonic Agents Market (Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。